Francesco Amati

Mar 6, 2024 | respiratory-research.biomedcentral.com | Francesco Amati |Anna Stainer |Stefano Aliberti

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

Dec 16, 2023 | respiratory-research.biomedcentral.com | Andrea Gramegna |Andrea Lombardi |Margherita Ori |Francesco Amati |Mariangela Retucci |Gianfranco Alicandro | +9 more

Treatment with low-dose azithromycin is beneficial in pwCF and chronic P. aeruginosa mainly due to its immunomodulatory and anti-inflammatory properties [106]. The efficacy of macrolides does not appear to derive from the antibiotic effect but is mediated by inhibiting biofilm formation and other bacterial virulence factors. This results in improved lung function and reduced exacerbation rates in this group of patients [107]. Macrolides are also a key drug in the clinical management of NTM-PD.